Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003176 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00003176 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 82 participants.
The verdict
NCT00003176, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
Interventions
- DRUG temozolomide
- DRUG carmustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 1998-03-25 |
| Est. Completion | 2004-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003176
The ClinicalTrials.gov registry entry for NCT00003176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00003176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003176 about?
NCT00003176 is a clinical study titled "Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glio...
What is the current status of trial NCT00003176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 1998-03-25. Estimated completion is 2004-01-06.
What interventions are being tested in trial NCT00003176?
The interventions under investigation include: temozolomide (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00003176?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.